Document is current
Any future updates will be listed below
-
Authors
Abusamra, Sophia M. https://orcid.org/0000-0001-9588-5005
Anbarasan, Thineskrishna
Cotton, Daniele T. https://orcid.org/0000-0002-3321-8554
Ranasinha, Nithesh M. S.
Barber, Robert
Bridge, Suzannah https://orcid.org/0009-0003-9836-9200
Smith, Carolyn https://orcid.org/0000-0001-7196-9116
Figiel, Sandy https://orcid.org/0000-0003-3889-3468
Yin, Wencheng
Davis, Jason J.
Salami, Simpa S. https://orcid.org/0000-0001-7461-7079
Hamdy, Freddie C.
Bryant, Richard J. https://orcid.org/0000-0002-8330-9251
Lu, Yong-Jie https://orcid.org/0000-0001-6174-6621
Mills, Ian G. https://orcid.org/0000-0001-5347-5083
Edwards, Claire M.
Morgan, Todd M. https://orcid.org/0000-0002-1140-0603
Lamb, Alastair D.
- License Information
-
More Information
Article History
Accepted: 10 December 2025
First Online: 16 January 2026
Competing interests
: S.M.A., C.M.E. and A.D.L. have received support from BioRad through the Celselect grant. T.M.M. is on the advisory boards for Merck, Foundation Medicine, Johnson & Johnson and Pfizer. A.D.L. has received educational support from GlaxoSmithKline, Astellas, Lilly, AstraZeneca and Ipsen. A.D.L. and F.C.H. have paid roles as BJUI Editors. Y.J.L. has received support from ANGLE PLC for his circulating tumour cell study. A.D.L. has received honoraria for reviewing for European Urology and Lancet Oncology. A.D.L. has received consulting fees from AlphaSights. A.D.L. undertakes medicolegal expert witness work related to prostate cancer management in the UK. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The other authors declare no competing interests.
